BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu T, Konyn PG, Cattaneo AW, Saab S. New Face of Hepatitis C. Dig Dis Sci 2019;64:1782-8. [PMID: 30756208 DOI: 10.1007/s10620-019-05511-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-8. [PMID: 31366455 DOI: 10.1136/gutjnl-2019-318813] [Cited by in Crossref: 149] [Cited by in F6Publishing: 114] [Article Influence: 74.5] [Reference Citation Analysis]
2 Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Reference Citation Analysis]
3 Vyhmeister R, Enestvedt CK. The Changing Liver Transplant Recipient: From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol. Clin Liver Dis 2021;25:137-55. [PMID: 33978575 DOI: 10.1016/j.cld.2020.08.012] [Reference Citation Analysis]
4 Winetsky D, Zucker J, Slowikowski J, Scherer M, Verna EC, Gordon P. Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C? Open Forum Infect Dis 2019;6:ofz178. [PMID: 31123691 DOI: 10.1093/ofid/ofz178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Adler Jaffe S, Myers O, Meisner ALW, Wiggins CL, Hill DA, McDougall JA. Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. Cancer Epidemiol Biomarkers Prev 2020;29:300-7. [PMID: 31796525 DOI: 10.1158/1055-9965.EPI-19-0902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saab S, Kullar R, Amini C, Gounder P. WITHDRAWN: The next frontier: universal hepatitis C virus screening in pregnant women. Am J Obstet Gynecol 2020:S0002-9378(20)30133-2. [PMID: 32044311 DOI: 10.1016/j.ajog.2020.01.058] [Reference Citation Analysis]
7 Pearce ME, Yu A, Alvarez M, Bartlett SR, Binka M, Jeong D, Clementi E, Adu P, Wilton J, Yoshida EM, Pick N, Buxton JA, Wong J, Jassem A, Krajden M, Janjua NZ. Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019. PLoS One 2020;15:e0244575. [PMID: 33382774 DOI: 10.1371/journal.pone.0244575] [Reference Citation Analysis]
8 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
9 Halket D, Dang J, Phadke A, Jayasekera C, Kim WR, Kwo P, Downing L, Goel A. Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. J Gen Intern Med 2022. [PMID: 35230622 DOI: 10.1007/s11606-022-07460-1] [Reference Citation Analysis]
10 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Marascio N, Mazzitelli M, Scarlata GG, Giancotti A, Barreca GS, Lamberti AG, Divenuto F, Costa C, Trecarichi EM, Matera G, Liberto MC, Torti C. HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018). TOMICROJ 2020;14:84-90. [DOI: 10.2174/1874285802014010084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Verma D, Ashkar C, Saab S. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations. Expert Rev Pharmacoecon Outcomes Res 2021;21:9-12. [PMID: 33073620 DOI: 10.1080/14737167.2021.1838898] [Reference Citation Analysis]
13 Saab S, Kullar R, Khalil H, Gounder P. Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review. J Clin Gastroenterol 2021;55:250-7. [PMID: 32324677 DOI: 10.1097/MCG.0000000000001360] [Reference Citation Analysis]
14 Bobardt M, Hansson MJ, Mayo P, Ure D, Foster R, Gallay P. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLoS One 2020;15:e0237236. [PMID: 32764799 DOI: 10.1371/journal.pone.0237236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Tanoglu A. Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:664-5. [PMID: 32251207 DOI: 10.1097/MEG.0000000000001657] [Reference Citation Analysis]
16 Goldstein ND, Kahal D, Testa K, Burstyn I. Inverse probability weighting for selection bias in a Delaware community health center electronic medical record study of community deprivation and hepatitis C prevalence. Ann Epidemiol 2021;60:1-7. [PMID: 33933628 DOI: 10.1016/j.annepidem.2021.04.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]